Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by University of Patras
Sponsor:
Information provided by (Responsible Party):
Dimitrios Alexopoulos, University of Patras
ClinicalTrials.gov Identifier:
NCT01961856
First received: October 9, 2013
Last updated: November 5, 2013
Last verified: November 2013

October 9, 2013
November 5, 2013
September 2013
January 2014   (final data collection date for primary outcome measure)
Platelet Reactivity between the two groups at 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01961856 on ClinicalTrials.gov Archive Site
Platelet reactivity between the two groups at 4 hours [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
Same as current
  • Platelet reactivity between the two groups at hour 2 [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
  • Percentage of patients presenting high platelet reactivity (HPR) (≥208 PRU) between the two groups at hour 2 [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
  • Percentage of patients presenting high platelet reactivity (HPR) (≥208 PRU) between the two groups at hour 4 [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
  • Percentage of patients presenting high platelet reactivity (HPR) (≥208 PRU) between the two groups at hour 6 [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
  • Percentage of patients presenting high platelet reactivity (HPR) (≥208 PRU) between the two groups at hour 24 [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • Overall ST segment deviation in all electrocardiogram leads except aVR between groups at 90 min after first balloon inflation [ Time Frame: 90 min ] [ Designated as safety issue: No ]
  • Overall ST segment deviation in all electrocardiogram leads except aVR between groups at 180 minutes after the first balloon inflation [ Time Frame: 180 minutes ] [ Designated as safety issue: No ]
  • Overall ST segment deviation in all electrocardiogram leads except aVR between groups at discharge [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST deviation in all leads except aVR (in comparison to hour 0) at 90 minutes after the first balloon inflation, between the two groups. [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST deviation in all leads except aVR (in comparison to hour 0) at 180 minutes after the first balloon inflation, between the two groups. [ Time Frame: 180 minutes ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST deviation in all leads except aVR (in comparison to hour 0)at discharge, between the two groups. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST elevation in all leads except aVR (in comparison to hour 0) at 90 minutes after the first balloon inflation, between the two groups. [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST elevation in all leads except aVR (in comparison to hour 0) at 180 minutes after the first balloon inflation, between the two groups. [ Time Frame: 180 minutes ] [ Designated as safety issue: No ]
  • Percentage of patients with ≥50% resolution of ST elevation in all leads except aVR (in comparison to hour 0) at discharge between the two groups. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Overall ST segment elevation in all electrocardiogram leads except aVR between groups at 90 min after first balloon inflation [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]
  • Overall ST segment elevation in all electrocardiogram leads except aVR between groups at 180 min after first balloon inflation [ Time Frame: 180 min ] [ Designated as safety issue: No ]
  • Overall ST segment elevation in all electrocardiogram leads except aVR between groups at discharge [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Area under the curve (AUC) defined by Troponin I values assessed at 0 hour, 4, 12, 24, 48 and 72 hours between the two groups. [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • Area under the curve (AUC) defined by CK-MB values assessed at 0 hour, 4, 12, 24, 48 and 72 hours between the two groups. [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Same as current
 
Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
Platelet Reactivity After Ticagrelor Loading Dose Versus Clopidogrel Loading Dose and Reloading With Ticagrelor, in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention (PCI).

In the PLATO substudy referring to patients presenting with an ST-elevation Myocardial Infarction(STEMI), out of the 4201 who received ticagrelor, 1326 had been pre-treated with a 600mg clopidogrel loading dose (LD) within 24 hours prior to randomization. It is a logical assumption, that patients who are being reloaded with ticagrelor will demonstrate reduced platelet reactivity (PR) at 24 hours, in comparison to those who were initially loaded with ticagrelor, due to the synergistic antiplatelet effect. Single loading with ticagrelor though, will possibly be accompanied by a smaller bleeding potency compared to reloading with ticagrelor. Therefore, we assume that single loading with ticagrelor is non-inferior to reloading with ticagrelor, in terms of platelet reactivity.

P2Y12 inhibitor naive patients with STEMI, they will be randomized immediately after coronary angiography (Hour 0) in receiving either Ticagrelor 180mg LD or Clopidogrel 600mg LD and 2 hours later reloading with Ticagrelor 180mg, after written informed consent. PR will be measured, using the VerifyNow assay at randomization (Hour 0) and at 2, 4, 6 and 24 hours post randomization. In addition, a 12-lead ECG will be performed before randomization, 90 and 180 minutes after the first balloon inflation, as well as on the exit day. Troponin I and CK-MB will be assessed at randomization and at hour 4, 12, 24, 48 and 72 after randomization.

Non inferiority of Ticagrelor LD versus Ticagrelor re-LD would be accepted if the upper bound of the 2-sided 95% CI around the estimated LS mean difference (Ticagrelor LD minus Ticagrelor re-LD) in the primary end point (PR at 24 hours) would lie bellow Δ=35 PRU. This non-inferiority margin (Δ) represents the upper bound of the LS mean difference in PR between Ticagrelor and Prasugrel arm at 24 hours after LD in a pharmacodynamic study of 55 STEMI patients.

Considering previous studies PR at 24 hours post randomization was estimated at 47±40 PRU and 41±35 PRU for Ticagrelor only LD and Ticagrelor re-LD group respectively. To obtain 85% statistical power with a 2-sided alpha=0.05, approximately 32 patients in each treatment group (64 in total) would be needed to establish the primary hypothesis using the abovementioned non-inferiority margin of 35 PRU. Anticipating a 5% dropout rate, enrollment was set to at least 68 patients. The primary endpoint, as well as PR at all the other time points of the study will be analyzed separately via a mixed effect model with treatment as fixed effect, patient as a random intercept and PR at baseline as a covariate. Least squares estimates of the mean difference will be presented, with 95% confidence intervals and a two-sided p-value for the treatment effect. P values for secondary endpoints will be reported for two-tailed tests of superiority.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Platelet Reactivity
  • Drug: Clopidogrel and Ticagrelor
    Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
  • Drug: Ticagrelor
    Ticagrelor 180mg loading dose
  • Active Comparator: Ticagrelor
    Ticagrelor 180mg loading dose
    Intervention: Drug: Ticagrelor
  • Experimental: Clopidogrel and Ticagrelor
    Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
    Intervention: Drug: Clopidogrel and Ticagrelor
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
68
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-80 years old
  • Patients with STEMI (pain onset <12 hours) undergoing primary PCI
  • P2Y12 inhibitor naive
  • Written informed consent

Exclusion Criteria:

  • Peri-procedural IΙb/IIIa inhibitor administration
  • Cardiogenic shock/hemodynamic instability
  • Pseudo-aneurism, retroperitoneal hematoma, major bleeding (need for transfusion or Hb decline≥5 gr/ dl)
  • Need for anticoagulant treatment
  • Current or future administration of other thienopyridines or ADP receptor inhibitors
  • Known thrombocytopenia (<100.000 / μL) at randomization
  • Hct <30% or Hct > 52% during randomization
  • Known allergy to clopidogrel or ticagrelor
  • Recent (< 6 weeks) major operation, including CABG
  • History of bleeding disorders
  • Known intracranial mass, arteriovenous shunt or aneurism
  • Previous intracranial bleeding
  • INR>1,5
  • Other clinical conditions associated with increased bleeding risk, according to the investigators' judgment
  • Known creatinine Clearance <30ml/h at randomization or hemodialysis
  • Severe/moderate liver failure
  • Pregnancy/ breastfeeding
  • Increased risk for bradyarrhythmias, according to the investigator's judgment
  • Administration of potent CYP3A inhibitor (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice N1 L/d), substrates of CYP3A with narrow therapeutic range (cyclosporine, quinidine), or potent CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine)
  • Severe uncontrolled chronic obstructive pulmonary disease
Both
18 Years to 80 Years
No
Contact: Dimitrios Alexopoulos, Professor 00302610999281 dalex@med.upatras.gr
Greece
 
NCT01961856
PATRASCARDIOLOGY-17
No
Dimitrios Alexopoulos, University of Patras
University of Patras
Not Provided
Not Provided
University of Patras
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP